Relay Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $901.00K, a 37.98% increase year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $653.00K, a 42.16% decline year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $732.00K.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $1.13M, a 30.61% decline year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.08M, a 26.98% decline from fiscal 2024.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.48M, a 40.51% decline from fiscal 2023.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.49M, a 47.45% increase from fiscal 2022.
- Relay Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.69M, a 47.77% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $901.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.08M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $653.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.48M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $732.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.13M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.49M 10-K · filed 2026-02-26 | |
| 2023-06-30 | $1.63M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.69M 10-K · filed 2025-02-26 | |
| 2022-06-30 | $1.14M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $1.14M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |